" /> Hyperphenylalaninemia, bh4-deficient, a - CISMeF





Preferred Label : Hyperphenylalaninemia, bh4-deficient, a;

Symbol : HPABH4A;

CISMeF acronym : HPABH4A;

Type : Phenotype, molecular basis known;

Alternative titles and symbols : Hyperphenylalaninemia, tetrahydrobiopterin-deficient, due to pts deficiency; 6-pyruvoyl-tetrahydropterin synthase deficiency; Pts deficiency; PTSD; PTPSD;

Included titles and symbols : Hyperphenylalaninemia, bh4-deficient, due to partial pts deficiency;

Description : Tetrahydrobiopterin (BH4)-deficient hyperphenylalaninemia (HPA) comprises a genetically heterogeneous group of progressive neurologic disorders caused by autosomal recessive mutations in the genes encoding enzymes involved in the synthesis or regeneration of BH4. BH4 is a cofactor for phenylalanine hydroxylase (PAH; 612349), tyrosine hydroxylase (TH; 191290) and tryptophan hydroxylase (TPH1; 191060), the latter 2 of which are involved in neurotransmitter synthesis. The BH4-deficient HPAs are characterized phenotypically by hyperphenylalaninemia, depletion of the neurotransmitters dopamine and serotonin, and progressive cognitive and motor deficits (Dudesek et al., 2001).;

Inheritance : Autosomal recessive;

Molecular basis : Caused by mutation in the 6-@pyruvoyl-tetrahydropterin synthase gene PTS, (612719.0001);

Laboratory abnormalities : Hyperphenylalaninemia; Decreased homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) in CSF; Increased neopterin in urine and CSF; Decreased or absent PTS activity;

Prefixed ID : #261640;

Details


You can consult :


Nous contacter.
17/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.